Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) recently announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) will initiate a mechanism-of-action study to evaluate Pluristem's PLacental eXpanded RAD (PLX-RAD) cells for the treatment of acute radiation syndrome (ARS).

The study is expected to start later this month. NIAID aims to evaluate the impact of PLX-RAD cells on body weight, blood count parameters, cytokine concentrations and bone marrow at various intervals following the administration of PLX-RAD cells in animals.

NIAID expects to expand the scope of its PLX-RAD research if the data from this study on irradiated animals' hematological systems turns out to be positive.

Meanwhile, Pluristem is also evaluating PLX-RAD cells in the treatment of bone marrow failure following radio- or chemotherapy. The study is currently in preclinical stages and Pluristem hopes to benefit from the data from the NIAID studies.

Pluristem develops and manufactures cell therapy products in collaboration with companies like United Therapeutics (UTHR - Analyst Report) or through research and clinical institutions.

The cells from placenta are derived using the company’s proprietary PluriX therapy and are known as PLacental eXpanded cells. Pluristem's first candidate in development, PLX-PAD, is intended to treat peripheral artery disease (PAD).

We note that Pluristem intends to develop and produce cell therapy products for the treatment of multiple disorders using several methods of administration.

Last month, Pluristem released positive top-line results from a phase I/II trial evaluating the safety and efficacy of PLX-PAD cells in the treatment of muscle injury. The study met both the primary and secondary endpoints. The results from the trial showed that PLX-PAD cells were safe and statistical significance was reached for the primary efficacy endpoint.

The results indicated that PLX cells might be efficacious in the treatment of orthopedic injuries including muscles and tendons.

We are encouraged by Pluristem’s efforts to evaluate the efficacy of PLX-PAD cells for various indications. Pluristem currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector include Actelion (ALIOF) and Biogen Idec Inc. (BIIB - Analyst Report). Both carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%